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/kg) were administered intravenously, 1 day before MHCmismatched renal transplantation to rhesus monkeys treated with costimulation blockade (cytotoxic T lymphocyte Ag 4 immunoglobulin [CTLA4] Ig) and tapered rapamycin. Prolongation of graft median survival time from 39.5 days (no DCreg infusion; n = 6 historical controls) and 29 days with control unpulsed DCreg (n = 2), to 56 days with donor Agpulsed DCreg (n = 5) was associated with evidence of modulated host CD4 + and CD8 + T cell responses to donor Ag and attenuation of systemic IL-17 production. Circulating anti-donor antibody (Ab) was not detected until CTLA4 Ig withdrawal. One monkey treated with donor Ag-pulsed DCreg rejected its graft in association with progressively elevated anti-donor Ab, 525 days posttransplant (160 days after withdrawal of immunosuppression). These findings indicate a modest but not statistically significant beneficial effect of donor Ag-pulsed autologous DCreg infusion on NHP graft survival when administered with a minimal immunosuppressive drug regimen.
Abbreviations: Ab, antibody; Ag, antigen; CoSB, costimulation blockade; CTLA4(Ig), cytotoxic T lymphocyte antigen 4 (immunoglobulin); DCreg, regulatory dendritic cells; IS, immunosuppression/immunosuppressive; MST, median survival time; NHP, nonhuman primate;
Introduction
Based on encouraging results in rodents, increasing attention has been paid to the potential of regulatory innate or adaptive immune cells as therapeutic cell-based vectors for promotion of long-term graft survival and induction of donor-specific tolerance. Several phase I/II safety studies are already under way (https://clinicaltrials. gov/ct2/show/NCT02088931; NCT02091232; NCT0212 9881; NCT02188719; NCT02244801). In addition to regulatory T cells (Treg) (1) (2) (3) , attention is focused on the therapeutic application of systemically administered regulatory myeloid cells (4) (5) (6) (7) , in particular regulatory dendritic cells (DC; DCreg) (8) (9) (10) (11) .
In the healthy steady-state, DC maintain peripheral self-tolerance (12, 13) and therefore prevent fatal, spontaneous autoimmune disease (14) . Thus, quiescent immature/semimature DC control T cell activation against self antigens (Ags), promote deletion of memory T cells (Tmem), and prevent recall responses to cognate Ag in vivo (15) (16) (17) . We first reported that ex vivo-generated DC expressing low levels of surface MHC and costimulatory molecules could induce alloAg-specific T cell hyporesponsiveness (18) when administered intravenously (i.v.) and prolong heart or pancreatic islet allograft survival in mouse models (19, 20) . Subsequent reports have demonstrated that immature, maturation-resistant DCreg, infused either alone or with an immunosuppressive (IS) agent(s), can promote indefinite organ, islet, or skin allograft survival in rodents (8, (21) (22) (23) (24) (25) (26) (27) (28) (29) . Furthermore, systemic administration of DCreg prevents graft-versus-host disease in experimental models of hematopoietic stem cell transplantation (30) (31) (32) (33) .
Recent studies have demonstrated the ability of adoptively transferred DCreg to modulate alloimmune responses in nonhuman primates (NHP) (34, 35) , the immune systems of which more closely resemble those of humans than do those of mice. In addition, we have reported that donor-derived DCreg, generated ex vivo from peripheral blood monocytes and infused a week before transplant, can safely prolong life-sustaining MHCmismatched renal allograft survival in NHP treated with a minimal IS regimen (36) . These findings provide justification for phase I clinical testing of donor-derived DCreg in living donor organ transplantation (37) . Donor-derived DCreg are not the only type of DCreg that could potentially be used for therapeutic purposes. There is also evidence that unpulsed or donor Ag-pulsed autologous/syngeneic DCreg infused either 1 day before transplant, with or without suboptimal IS (26, 28, 38) , or after transplant (39, 40) , can promote donor-specific tolerance in murine models. In principle, this alternative approach could allow more generalized application of DCreg therapy to include deceased donor transplantation. In the present study, we examined the influence of systemic administration of autologous, monocyte-derived, untreated or donor Ag-pulsed DCreg, infused i.v. a day before transplant, on MHC-mismatched renal allograft survival in rhesus macaques. We used the same minimal IS regimen (costimulation blockade [CoSB] and tapered mechanistic target of rapamycin inhibition) with which we previously demonstrated (36) the ability of donorderived DCreg to prolong graft survival in the same setting. Our findings show that, compared with no cell infusion or unpulsed autologous DCreg infusion, autologous DCreg preloaded with donor Ag in the form of cell membrane vesicles (41) modestly but not significantly extend median graft survival time in this clinically relevant model, without host sensitization and with evidence of modulation of anti-donor T cell responses.
Materials and Methods

Experimental animals
Captive-bred, simian immunodeficiency virus-negative, herpes B virusnegative, male juvenile Indian rhesus macaques (Macacca mulatta; n = 11 combined donors and recipients) weighing 5-7 kg were used. They were obtained from the National Institute of Allergy and Infectious Diseases-sponsored rhesus macaque colony (Yemasse, SC) and maintained in the NHP Research Facility of the Department of Laboratory Animal Resources at the University of Pittsburgh School of Medicine. All procedures and medications were approved by the University of Pittsburgh Institutional Animal Care and Use Committee. Experiments were conducted according to the guidelines set forth in the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Specific environment enrichment was provided.
MHC typing
MHC typing was performed as described (42) . The degree of disparity between allograft donors and recipients that were mismatched in at least five of six Mamu-A, -B, and -DRB haplotypes is shown in Table S1 .
Recipient leukapheresis
To mobilize blood monocytes, prospective transplant recipients underwent cytokine treatment and leukapheresis as described (34) . Peripheral blood mononuclear cells (PBMC) were stored in liquid N 2 until DCreg generation. A minimum interval of 28 days was implemented before transplant surgery to allow restoration of normal leukocyte levels.
Preparation of cell membrane vesicles from donor PBMC
The protocol used was similar to that described by Kovar et al (41) for producing small membrane vesicles that resemble exosomes in size and morphology. The vesicles were prepared fresh each time from thawed rhesus PBMC. The cells were washed with phosphate-buffered saline (PBS) and incubated with hypotonic buffer (1 M HEPES, 1 M MgCl 2 , 2.5 M KCl, 1M dithiothreitol, distilled water up to 10 mL, and 1 tablet of EDTA-free protease inhibitor cocktail [Roche, Indianapolis, IN]) for 10 min on ice. Thereafter, the cell suspension was sonicated eight times for 10 s each, in order to disrupt the cells and generate vesicles from the plasma membrane. To isolate the vesicles, samples were centrifuged at 500g 4°C for 10 min, supernatants recovered and ultracentrifuged at 500g 4°C for 1 h, and the pellet resuspended in 200-500 lL PBS. Protein quantification was performed using NanoDrop spectrophotometry (Thermo Scientific, Waltham, MA).
Generation of DCreg
DCreg were generated as described (34) from immunobead-purified CD14 + monocytes in recombinant human (rhu) granulocyte-macrophage colony-stimulating factor + rhu IL-4 over 7 days, with the addition of vitamin D3 (VitD3) on days 1 and 5, and rhu IL-10 on day 5. Control, immunostimulatory DC were generated similarly, but without addition of VitD3 or IL-10, and in the presence of a proinflammatory cytokine cocktail (tumor necrosis factor a, IL-1b, and IL-6) for the final 24 h of culture (34) .
Loading of vesicles and characterization of Ag-pulsed DCreg
Vesicles generated from prospective transplant donor PBMC were incubated with recipient-derived DCreg for 18-20 h (37°C; 5% CO 2 ) at 10-50 lg vesicles per 10 5 DCreg. To examine their capture by DCreg, the vesicles were prelabeled with the red membrane dye PKH26 (Sigma-Aldrich, Saint Louis, MO; PKH26GL), following the manufacturer's protocol before incubation with the DCreg. Vesicle capture was then evaluated by flow cytometry.
To characterize the phenotype of DCreg loaded with donor-derived vesicles, the cells were stained with the following monoclonal antibodies (mAbs): APC-HLA-DR (G46-6), PerCP-Cy5.5-CD86 (FUN-1), V450-CD80 (L307.4), fluorescein isothiocyanate (FITC)-CD83 (HB15E) (all from BD Biosciences, San Jose, CA) and PE-Cy7-programmed death-ligand (PD-L)1 (29E.2A3) (Biolegend, San Diego, CA), then analyzed by flow cytometry. For functional assessment, DCreg or control DC were cultured with autologous T cells at 1:40 ratio for 4-5 days. The cultures were then split; one half was used to measure T cell proliferation by 3 H-thymidine incorporation and the other half rested for 3 days before restimulation with allogeneic PBMC from the same donor as the vesicles at 1:10 (PBMC:T cell) ratio for 3 days. Proliferation was measured by 3 H-thymidine incorporation.
Renal transplantation
Renal transplantation was conducted and the experimental end-point determined as described (36, 43) .
Cytomegalovirus (CMV) detection
Real-time polymerase chain reaction (Zoologix, Chatsworth, CA) was used to detect CMV in serum samples obtained at the time of euthanasia.
DCreg infusion and IS therapy
The experimental protocol is shown in Figure 1 . As described previously for the infusion of autologous DC in rats (26) , autologous rhesus DCreg (preloaded or not with donor-derived vesicles [0.9-3.6 9 10 6 DCreg/kg body weight]) were infused i.v., 1 day before transplantation (i.e. on day À1). All graft recipients received CTLA4Ig (abatacept; Bristol-Myers Squibb, Princeton, NJ; 20 mg/kg, i.v.) on days À1, 0, 4, 7, 10, and 14, then weekly until day 56. Intramuscular rapamycin (LC Laboratories, Woburn, MA) was given daily, starting on day À2 for 6 months, with whole blood levels maintained between 10 and 15 ng/mL for the first month, between 5 and 10 ng/mL during the subsequent 4 months, and between 1 and 5 ng/mL for the following month. Historical control group recipients received either short-term CTLA4Ig on days À1, 0, 2, 4, 7, and 10, or long-term CTLA4Ig on days À1, 0, 3, 7, 10, and 14, then weekly until day 56 if survival extended beyond day 28 posttransplant. In all groups, IS therapy was discontinued 6 months posttransplant.
Measurement of circulating alloantibody (alloAb) levels
Serum samples were stored at À20°C. Donor CD3 + T cells (from spleen or lymph nodes) were used as targets for quantitation of anti-donor MHC class-I IgG alloAb by flow cytometry, as described (44, 45) . APC-CD3 Ab (SP34-2) was obtained from BD Biosciences and FITC-goat anti-human IgG from Invitrogen (Carlsbad, CA).
Monitoring of anti-donor T cell reactivity
PBMC were isolated before and 1 month after transplantation. CD2 + T cells were purified by positive selection with anti-human CD2 microbeads (Miltenyi Biotec, Auburn, CA) according to the manufacturer's procedure. Anti-donor proliferative responses were determined in 4-5-day Carboxyfluorescein succininidyl ester (CFSE) -mixed lymphocyte reaction (MLR), as described (36) . Figure 1 : Protocol for generation, Ag pulsing, and infusion of autologous DCreg into renal-allografted rhesus monkeys treated with CTLA4Ig and tapered rapamycin. Times of IS drug (CTLA4Ig and rapamycin) administration in relation to the day of transplant (on day 0) are shown. All graft recipients in each group received CTLA4Ig (abatacept; Bristol-Myers Squibb, Princeton, NJ; 20 mg/kg, i.v.) on days À1, 0, 4, 7, 10, 14, 21, 28, 35, 42, 49, and 56. Intramuscular rapamycin (LC Laboratories, Woburn, MA) was given daily, starting on day À2 for 6 months. Whole blood trough levels of rapamycin were measured twice weekly and maintained between 10 and 15 ng/mL for the first month, between 5 and 10 ng/mL during the subsequent 4 months, and between 1 and 5 ng/ mL for the following month. IS therapy was discontinued 6 months posttransplant. Ag, antigen; CTLA4Ig, cytotoxic T lymphocyte antigen 4 (immunoglobulin); DCreg, regulatory dendritic cells; IS, immunosuppression; Tx, transplant. 
Phenotypic analysis of donor-reactive T cells
Following their coculture with donor cells, fluorochrome-labeled mAbs were used for cell surface or intracellular staining of recipient T cells, as described in Data S1.
Intracellular cytokine staining and cytokine quantitation
Intracellular cytokine staining of T cells and cytokine assays were performed as described in Data S1.
Graft histology
Hematoxylin and eosin-stained sections were scored for rejection based on Banff criteria (46) by a transplant pathologist (MM) "blinded" to the identity of the graft recipients.
Statistical analyses
Graft survival curves were compared by log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon tests using prism software. Significances of
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Results
Rhesus monocyte-derived DCreg capture allogeneic (donor) vesicles efficiently First, we examined the ability of rhesus blood monocytederived DCreg to capture cell membrane vesicles generated from allogeneic PBMC. The vesicles were labeled on the membrane with a fluorescent dye (PKH26) and cultured at increasing concentrations with DCreg or with control immunostimulatory DC for 16-18 h. As shown in Figure 2 (A), both DCreg and control DC captured donor vesicles in a vesicle dose-dependent manner. Notably, DCreg, consistent with their comparative immaturity (34), were more efficient than control stimulatory DC at acquiring the donor vesicles ( Figure 2B ).
Capture of donor Ag by rhesus DCreg does not modify their surface phenotype Next, we tested whether loading with donor vesicles affected the surface phenotype of the rhesus DCreg. Measurement of surface expression of MHC class II (HLA-DR), coregulatory molecules (CD80, CD86, and PD-L1) and the DC maturation marker CD83 by flow cytometry revealed no significant difference in the incidence of positive cells or mean fluorescence intensity, before and after loading with the donor vesicles ( Figures 2C and D) .
Presentation of donor Ag by DCreg to autologous T cells
We then evaluated the capacity of the rhesus DC to present donor Ags by performing cocultures of vesicle-loaded DC with autologous T cells and measuring T cell proliferation after 4 days. The results show a significant (approximately twofold) increase in T cell proliferation when autologous stimulatory DCs were loaded with 50 lg of allogeneic vesicles compared with nonstimulated T cells ( Figure 3A) . By contrast, DCreg loaded with the same amount of allogeneic vesicles (50 lg) failed to stimulate T cell proliferation ( Figure 3A) . To test the stability of this presumed hyporesponsiveness, the primed T cells were rested for 3 days, then restimulated with allogeneic PBMC from the same donor as the vesicles. As shown in Figure 3(B) , proliferation of T cells primed with donor vesiclepulsed control DCreg was significantly lower than that of T cells primed with donor vesicle-pulsed control stimulatory DC at 25 and 50 lg (p < 0.05 and p < 0.005, respectively). Furthermore, the response of T cells primed by donor vesicle-pulsed stimulatory DC to restimulation with donor Ag was significantly higher than that of T cells primed with unpulsed stimulatory DC, whereas that of T cells primed by either unpulsed or pulsed DCreg was not significantly different, indicating their hyporesponsiveness to secondary Ag challenge.
Donor Ag-pulsed autologous DCreg increase median renal allograft survival time Cuturi and colleagues (26, 28) have demonstrated that, in rodents, systemic administration of syngeneic immature DCreg (3 9 10 6 or higher) 1 day before organ transplantation prolongs graft median survival time (MST) significantly. They also demonstrated that neither an increase in cell dose, nor alteration of the timing of DCreg infusion (to day 0), nor additional cell infusion posttransplant (x1, x2) further improves graft survival. To test the in vivo efficacy of autologous DCreg, we determined the influence of either untreated or donor Ag-loaded DCreg on renal allograft survival. The DCreg were infused, as described in rodents (26,28), 1 day before transplant and according to the protocol shown in Figure 1 . The quantity of donor vesicles loaded and the number of pulsed DCreg infused into each graft recipient are shown in Table 1 . Serum creatinine levels, body weight loss, and allograft survival times are shown in Figures 4A-C. Mean weight loss at 2 and 4 weeks was 15% and 21% for the historical control group, 10% and 16% for the unpulsed DCreg group, and 10% and 12% for the donor Ag-pulsed DCreg group. Graft recipients M36 and M38 in the latter group whose creatinine did not increase and whose weight loss was <20% at 4 weeks exhibited continuous weight loss >20% at the time of euthanasia ( Figure S1 ). Serum samples obtained at the time of euthanasia were negative for CMV in all recipients, except M38, suggesting that CMV infection may have contributed to the increased weight loss observed in this monkey. Graft MST in the historical control group was 39.5 days (36) and in animals given unpulsed DCreg was 29 days (combined MST = 36 days), whereas in the group given donor alloAg-pulsed DCreg it was 56 days. Comparison of graft survival curves of combined historical control and unpulsed DCreg groups with the Ag-pulsed DCreg group revealed that they did not differ significantly. In one monkey (M50) given donor Ag-pulsed DCreg, graft survival time was 525 days (i.e. 345 days off all pharmacologic IS), without any prior episodes of rejection.
Histological analysis of the allografts
Histopathologic findings for each renal allograft determined at the time of clinical rejection are shown in Table S2 . All grafts demonstrated similar, mild, T cell-mediated rejection (Banff 1A-2A), with overall mild fibrosis/ tubular atrophy.
Absence of circulating donor-specific alloAb levels in allograft recipients while receiving CTLA4Ig Circulating anti-donor alloAb levels were determined in all graft recipients, before and after transplant. As shown in Figure 5 , no evidence of transplant-induced IgG alloAb production was observed in any of the graft recipients, except in one recipient (M49) in the historical control group on postoperative day 75, and in the monkey treated with donor Ag-pulsed DCreg in which graft survival was 525 days. In this latter animal, progressive increases in anti-donor Ab were observed from postoperative day 180, following withdrawal of CoSB.
Concomitant CTLA4 and PD-1 expression by donorreactive T cells
We did not observe any significant change in the incidences or absolute numbers of circulating Treg or Tmem or in the Tmem/Treg ratio in the blood of graft recipients following transplantation (data not shown). Additionally, there was no correlation between host T cell proliferative responses to donor (in CFSE-MLR) after transplantation and graft survival. Previously, we reported (36) that prolonged renal allograft survival in monkeys given donorderived DCreg together with the same IS regimen as used here was associated with enhanced co-expression of the exhaustion markers CTLA4 and programmed death-1 (PD-1) by donor-reactive T cells. This contrasted with their reduced expression by donor-reactive T cells from control graft recipients given no cell infusion. In the present study, concomitant CTLA4 and PD-1 expression by donorreactive CD4 + T cells was reduced significantly 4 weeks posttransplant (median = 17.1%) compared to pretransplant (median = 34.1%) in animals given either no or unpulsed DCreg (n = 4; p < 0.05) ( Figure 6A ), while in those given donor Ag-pulsed DCreg, it was not reduced posttransplant (median = 10.4%) compared to pretransplant (median = 14.9%). Similarly, whereas donor-reactive CD8 + T cells in monkeys given no or unpulsed DCreg also showed reduced concomitant CTLA4 and PD-1 expression posttransplant (median = 7.8%) compared to pretransplant (median = 11.9%), those given donor Ag-pulsed DCreg showed no overall reduction posttransplant (median = 6.9%) compared to pretransplant (median = 7%).
Concomitant Eomes and CTLA4 expression by donor-reactive CD8
+ T cells We have also reported (47) that prolonged renal allograft survival in monkeys given donor-derived DCreg is associated with an increased incidence of donor-reactive CTLA4 hi CD8 + T cells expressing low levels of the memory cell survival factor Eomesodermin (Eomes) posttransplant. In monkeys given either no or unpulsed autologous DCreg, the incidence of donor-reactive Eomes pretransplant (median = 16.6%) (p < 0.05), whereas in monkeys given Ag-pulsed autologous DCreg, the incidence of this subset was increased posttransplant (median = 8.1%) compared to pretransplant (median = 5.5%) ( Figure 6B ). Overall, these observations suggest that donor Ag-pulsed DCreg infusion is associated with maintenance of donor-reactive CD4/CD8 T cell exhaustion marker expression and reduced Eomes expression by donor-reactive CD8 + T cells.
Donor Ag-pulsed autologous DCreg infusion modulates pro-inflammatory IL-17 responses
The Th17 pathway has been implicated in acute T cell-mediated renal allograft rejection (48) (49) (50) . We therefore evaluated IL-17 expression by donor-reactive T cells pre-and 4 weeks posttransplant ( Figure 7A ). Increased incidences of donorreactive CD4 + IL-17 + T cells were observed post-(median = 7.2%) compared to pretransplant (median = 3.4%) in the two recipients given unpulsed DCreg (T cells from historical controls given no DCreg were no longer available for analysis). In contrast, in those monkeys given donor Agpulsed DCreg, the median percentage of donor-reactive CD4 We also investigated IL-17A, IL-21, and interferon c (IFN-c) levels in serum 4 weeks posttransplant. As shown in Figure 7(B) , IL-17A levels in graft recipients given no DCreg infusion (historical controls) were significantly higher 4 weeks posttransplant than in healthy normal animals (p < 0.05). Donor Ag-pulsed DCreg infusion was associated with reduced IL-17A to normal levels. In contrast, monkeys given unpulsed recipient DCreg showed an elevated median level of circulating IL-17A (similar to that with no DCreg infusion). The pattern observed for IL-21 was similar to that of IL-17A, although the differences were not statistically significant. There was no consistent pattern of IFN-c production by donor-reactive T cells posttransplant in either unpulsed or pulsed DCreg recipients, while a modest increase in serum IFN-c levels was detected in all recipients posttransplant, irrespective of DCreg infusion (data not shown). Altogether, these data suggest that donor Agpulsed DCreg infusion down-modulated pro-inflammatory (IL-17A) responses in the allograft recipients. + Th17 cells has recently been associated with CoSB resistance and human renal allograft rejection (52) . Thus, we evaluated co-expression of CTLA4 and IL-17 by donor-reactive CD4 + T cells in the autologous DCreg recipients pre-and posttransplant (Figure 8 ). In the monkeys given unpulsed DCreg, the incidence of 
donor-reactive CTLA4
+ IL-17 + T cells was increased twofold from 4.8% pre-to 10.2% posttransplant, in concert with increased donor-reactive CD4 + IL-17 + T cells (Figure 7A) . However, in recipients of donor Ag-pulsed DCreg, the mean incidence of donor-reactive CTLA4 + IL-17 + T cells did not change pre-and posttransplant (3.9 and 4.3%, respectively). These data suggest that donor Ag-pulsed DCreg infusion could modulate CD4 + IL-17 + cells in the graft recipients.
Discussion
Previous rodent studies by Cuturi and colleagues (26, 28) have shown that unpulsed syngeneic immature DC (DCreg) that do not stimulate T cells and resist maturation, prolong heart allograft survival in a nonspecific manner when infused 1 day before transplant. Indeed, in these rat studies, syngeneic DCreg were found to be more effective than donor DCreg (26) . As in the present NHP study, disparity in individual graft survival times was observed in the rats infused with syngeneic DCreg (10, 28) . However, this disparity was virtually eliminated and indefinite graft survival (donor-specific tolerance) achieved when the animals were given a nuclear factor jB inhibitor in conjunction with the syngeneic DCreg (26) . Subsequently, the same group has reported (53) that, following their infusion combined with anti-CD3 Ab, these unpulsed syngeneic DCreg cross-present graft-derived Ag to induce donor-specific CD8 + T cells with regulatory properties that prolong allogeneic skin graft survival.
Based on these studies in rodent models, it has been emphasized that the potential clinical utility of autologous DCreg as cellular therapeutics in organ transplantation may be greater than that of donor-derived DCreg, since the former do not need to be pulsed/loaded with donor MHC Ag to exert their regulatory function. It has also been argued that autologous DCreg could be used in either live or deceased donor transplantation. In the present study, however, unlike in the rodent reports, a single infusion of unpulsed autologous rhesus DCreg, 1 day before transplant, did not prolong graft survival.
The dose of autologous DCreg that we infused i.v. (approximately 2 9 10 6 /kg or 10 9 10 6 total cells) into the prospective monkey graft recipients was less than that (3 9 10 6 ) reported (26) to achieve maximal prolongation of heart allograft survival in rats (from 6 to 22 days) over a range of cell doses up to 15 9 10 6 . The failure of unpulsed autologous DCreg to alter graft survival in the present NHP study may be linked, in part, to an inability (unlike their Ag-pulsed counterparts) to modulate host anti-donor T cell responses, which are more prevalent in outbred NHP than in specific pathogen-free, comparatively short-lived, inbred rodents. Nevertheless, the modest prolongation of graft MST (to 56 days) that we observed with Ag-pulsed autologous DCreg was inferior to that we reported previously (114 days) for (similar doses of) donor-derived DCreg, infused 1 week before transplant (36) . Possible explanations for this difference may include the different doses of donor Ag delivered using intact allogeneic DCreg versus alloAg-pulsed autologous DCreg, and the timing of cell infusion.
It has been suggested that, unlike ex vivo-generated, donor-derived DCreg, which can regulate host alloimmunity and promote long-term graft survival/tolerance in rodents (8, 9) , non alloAg-pulsed syngeneic/autologous DCreg, such as those studied here in our monkey model, are not susceptible to killing by host natural killer cells/effector T cells. Significantly, however, in vivo survival/persistence of infused donor-derived DCreg may not be required to achieve their well-documented therapeutic effect (54) . Thus, once injected, these cells are short-lived and transfer donor alloAg to host conventional DC, which in turn reduce the alloimmune response and prolong graft survival (55, 56) . Indeed, DiVito et al (55) have shown that infusion of therapeutic, maturation-resistant donor DC (DCreg) results in presentation of alloAg by quiescent recipient DC in the context of self MHC class II, triggering deficient activation and deletion of effector T cells and increasing the incidence of indirect pathway CD4 + Foxp3 + Treg. Findings in mice also suggest that donor Ag-pulsed, recipient-derived DCreg that prolong graft survival (23, 27, 57) may also function via endogenous DC, since host DCreg pulsed with donor MHC allopeptide also fail to interact directly with T cells in vivo (55) . Such mechanisms may also underlie the capacity of autologous DCreg pulsed with donor Ag to prolong graft MST from 29 days (in recipients of similar numbers of unpulsed autologous DCreg) to 56 days in the present NHP study. Whether use of donorderived vesicles is the optimal approach for pulsing therapeutic autologous DCreg is uncertain. However, we found that this approach was readily standardized by quantifying the amount of vesicle protein delivered to the cells. Other potential sources of donor Ag that have been used to pulse autologous DCreg resulting in prolonged graft survival/tolerance in rodents include donor cell lysate (27, 57) , allopeptide (23) , or apoptotic cells (58) .
In this study, all of the NHP graft recipients given Agpulsed DCreg failed to develop anti-donor Ab up to 2 months posttransplant while receiving minimal IS (CTLA4Ig and tapered rapamycin), underscoring the low risk of host sensitization associated with infusion of either donor-derived DCreg (36) or host DCreg pulsed with alloAg (the present study) together with CoSB. The graft recipient given alloAg-pulsed DCreg that did not reject its graft until off all IS for almost 1 year eventually developed progressively elevated circulating IgG Ab levels after withdrawal of CoSB. Use of either CoSB or rapamycin has been shown previously to be compatible with and to enhance the tolerogenic function of adoptively transferred DCreg in rodent transplant models (29, 57) . Indeed, numerous diversely acting IS agents, including calcineurin inhibitors, corticosteroids, and mycophenolic acid, have been reported to potentiate the therapeutic efficacy of DCreg in experimental organ transplantation (8, 59 ).
In summary, donor Ag pulsing of autologous DCreg before their infusion was associated with a modest (but not statistically significant) increase in median graft survival time. This outcome was inferior to the significant therapeutic effect achieved with donor-derived DCreg infusion (36) . Notably, current innovative therapeutic approaches in human chronic inflammatory (autoimmune) disease include testing of Ag-pulsed, autologous DCreg (60, 61) .
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